Foresee Pharmaceuticals Submits NDA for CAMCEVI
Foresee Pharmaceuticals Co., Ltd. (TPEx: 6576) has announced the recent submission of a New Drug Application (NDA) for the 3-month version of CAMCEVI, a significant development for the treatment of advanced prostate cancer. This application has been submitted to the U.S. Food and Drug Administration (FDA), focused on providing patients with a ready-to-use depot formulation of leuprolide mesylate for effective palliative care.
Clinical Study Support
The NDA submission is bolstered by the results from a successful Phase 3 clinical trial involving 144 participants diagnosed with advanced prostate cancer. This study demonstrated the efficacy and safety of administering leuprolide mesylate every three months, with an impressive 97.9% of patients achieving the primary endpoint of efficacy. Such positive outcomes pave the way for expanding treatment options available to patients who need them.
Excitement Over New Development
Dr. Ben Chien, the Founder and Chairman of Foresee, expressed enthusiasm about the milestone reached with the NDA submission. Following the successful introduction of the 6-month depot formulation of CAMCEVI in 2022, this three-month version signifies a major step forward. The company is optimistic about receiving regulatory approval from the FDA within the next year and aims for a commercial launch shortly after, aiming to enhance the treatment experience for patients with advanced prostate cancer.
About the Company
Foresee Pharmaceuticals operates primarily in Taiwan and the U.S., and it lists on the Taipei Exchange under the ticker TPEx: 6576. The company is dedicated to innovative research and development in the biopharmaceutical field, focusing on two key areas: their unique Stabilized Injectable Formulation (SIF) technology which pertains to long-acting injectables for specialty markets, and their groundbreaking new chemical entities (NCE) targeting rare and severe diseases, where there's a significant unmet medical need.
Current Product Portfolio
Foresee’s product lineup includes both late-stage and early-stage programs. The CAMCEVI 6-month formulation for advanced prostate cancer is already approved in various regions including the U.S., Canada, the EU, and Israel. The company is currently preparing a regulatory submission for the 3-month version in the EU as well.
Investigation of New Indications
Beyond prostate cancer, Foresee is investigating additional indications for its 6-month depot formulation of CAMCEVI, including central precocious puberty (CPP), with ongoing Phase 3 trials. For premenopausal breast cancer, the company is also in the midst of clinical trials in China.
Innovative Products in Development
Foresee Pharmaceuticals is not limited to the CAMCEVI series; they also have several other promising products in their pipeline. Aderamastat (FP-025) targets inflammatory and fibrotic diseases and has shown positive results in studies with allergic asthmatic patients. To complement this, Linvemastat (FP-020) has successfully completed Phase 1 trials in healthy individuals and aims to tackle conditions like severe asthma and chronic obstructive pulmonary disease (COPD).
Future Endeavors
The company's dedication to advancing healthcare aligns with its ambitious plans for future studies, including Mirivadelgat (FP-045), which is focused on revolutionary treatments for conditions like pulmonary hypertension. With a keen eye on expanding their reach and developing new treatments, Foresee continues to pave the way for better health solutions for patients.
Frequently Asked Questions
What is the purpose of Foresee Pharmaceuticals' NDA submission?
The NDA submission aims to gain FDA approval for the 3-month version of CAMCEVI for the treatment of advanced prostate cancer, enhancing care options for patients.
What were the results of the Phase 3 clinical trial?
The Phase 3 study involved 144 patients and showed that treatment with the drug was effective and well-tolerated, achieving primary efficacy in 97.9% of the subjects.
When is the anticipated commercial launch of CAMCEVI?
The commercial launch is expected to occur in 2026, following the anticipated FDA approval in 2025.
What other indications is Foresee investigating?
Foresee is conducting clinical trials for indications such as central precocious puberty and premenopausal breast cancer, in addition to their prostate cancer therapies.
What innovative technologies does Foresee Pharmaceuticals utilize?
Foresee leverages a unique Stabilized Injectable Formulation (SIF) technology, focusing on long-acting injectables and new chemical entities targeting unmet medical needs.
